Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Name female reproductive organ cancer
Definition A reproductive organ cancer that is manifested in the female genitals. This includes organs such as the ovaries, fallopian tubes, uterus, cervix, vagina and vulva.
Source DiseaseOntology.org
Alt Ids DOID:1244 DOID:1281
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant Capivasertib female reproductive organ cancer predicted - sensitive detail...
BRAF D594N Trametinib female reproductive organ cancer no benefit detail...
BRAF N581S Trametinib female reproductive organ cancer no benefit detail...
ARID1A inact mut PLX2853 female reproductive organ cancer no benefit detail...
NRAS mutant Navitoclax + Trametinib female reproductive organ cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00800345 Phase I Pazopanib + Topotecan Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors Completed USA 0
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed USA | ESP 1
NCT03073525 Phase II Atezolizumab + FANG vaccine Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119) Completed USA 0
NCT03277482 Phase I Durvalumab + Tremelimumab Durvalumab Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Terminated USA 0
NCT04042116 Phase Ib/II Lucitanib + Nivolumab A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor Suspended USA | ITA | ESP | DEU | BEL | AUT 0
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting CAN 0
NCT04395079 Phase II Tremelimumab Durvalumab Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies Active, not recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT05238922 Phase I INCB123667 Study of INCB123667 in Subjects With Advanced Solid Tumors Recruiting USA | NLD | ITA | GBR | FRA 2
NCT05512208 Phase II Defactinib + RO5126766 A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) Recruiting USA 0
NCT05564377 Phase II Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Recruiting USA 1
NCT05636215 Phase Ib/II Orismilast A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05704985 Phase I DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors Recruiting USA 0
NCT05768139 Phase Ib/II Fulvestrant + STX-478 STX-478 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP 0
NCT05787561 Phase II Defactinib + RO5126766 A Study of VS-6766 and Defactinib in People With Mesonephric Gynecologic Cancer Recruiting USA 0
NCT06126276 Phase II Neratinib Neratinib + Palbociclib Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) Recruiting USA 0